WO2001088176A2 - Measurements of enzymatic activity in a single, individual cell in population - Google Patents

Measurements of enzymatic activity in a single, individual cell in population Download PDF

Info

Publication number
WO2001088176A2
WO2001088176A2 PCT/IL2001/000443 IL0100443W WO0188176A2 WO 2001088176 A2 WO2001088176 A2 WO 2001088176A2 IL 0100443 W IL0100443 W IL 0100443W WO 0188176 A2 WO0188176 A2 WO 0188176A2
Authority
WO
WIPO (PCT)
Prior art keywords
cell
process according
substrate
cells
measured
Prior art date
Application number
PCT/IL2001/000443
Other languages
French (fr)
Other versions
WO2001088176A3 (en
Inventor
Merav Sunray
Naomi Zurgil
Mordechai Deutsch
Original Assignee
Bar-Ilan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bar-Ilan University filed Critical Bar-Ilan University
Priority to US10/276,080 priority Critical patent/US20030211458A1/en
Priority to EP01934272A priority patent/EP1287160A4/en
Priority to JP2001584558A priority patent/JP2003533209A/en
Priority to AU60565/01A priority patent/AU6056501A/en
Publication of WO2001088176A2 publication Critical patent/WO2001088176A2/en
Publication of WO2001088176A3 publication Critical patent/WO2001088176A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions

Definitions

  • Enzymes are organic catalysts that cause and direct the numerous chemical
  • hving cells are caused and controlled by enzymes. Assessing the enzyme activity
  • the present invention provides a new process and methodology for measuring
  • the substrate is either passively
  • enzymes are important in diagnosing diseases. Most enzymes can be poisoned or
  • An enzymatic activity is usually characterized by two parameters: VMAX - the
  • FC Flow Cytometer
  • LSC Laser Scanning Cytometer
  • FC enables the rapid measurement of the fluorescence intensity ( FI ) of a large
  • the LSC measures the fluorescence kinetic of individual cells under specific
  • the LSC cannot ensure preservation of the cell locations and thus cell
  • identification might be lost during repeatable rinsing and exposure to different
  • the cytometer (hereinafter referred to as Cellscan Mark S or CS-S) which, one of
  • the same cells are sequentially exposed to increasing substrate concentrations.
  • the product formation rate is measured for each cell at every substrate
  • CS-S cytometer any cytometer comprising a microscope, light
  • detection means a carrier to which cells are individually located, is within the
  • the kinetic parameters are derived by application of linear and nonlinear
  • the CS-S algorithm uses ⁇ 2 as
  • Another aspect of present invention relates to sequential exposures of the same
  • stands for the time point of terminating the staining with a given substrate
  • Eq. 6 may be linearly
  • the substrate should be a substance
  • a further object of present invention is to provide a process for measuring
  • Fig. 1 A model of intracellular conversion of a substrate to a product.
  • ki is the rate constant for
  • k 2 is the rate constant for product formation.
  • Fig. 2 Simulation of an individual cell sequential FI time dependency following
  • Fig. 3 Experimental results of individual cells sequential staining procedure. The
  • Fig. 4 Complete sequential staining procedure of numerous cells. Each of the four clusters contains 13 lines. Each line defined by six FI measurements taken
  • Fig. 5 Individual KMAPP and VMAX for two representative cells and their Pearson
  • Fig. 6 The distribution of individual KMAPP (6A) and VMAX (6B) for cells that were
  • Fig. 7 Rate of change of FI before and after exposure of an individual cell to
  • H2O2 hydrogen peroxide
  • Example 1 Measuring intracellular nonspecific esterase activity in a single
  • FDA fluorescein-diacetate
  • Phytohemagglutinin PHA (HA15, Murex Biotech ) was reconstituted in 5 ml of
  • the culture medium consisted of RPMI-1640 (Biological Industries),
  • PBMC Peripheral Blood Mononuclear Cells
  • the cells were defined as T lymphocytes and viability, which was determined
  • central feature is a cell carrier (CC) incorporating a 100 x 100 dimensional array
  • the cell carrier is mounted on a computer-controlled stage that enables repeated
  • the acquired data including cell position, measurement duration for each cell,
  • sub -population or an individual cell, before, or during the scan.
  • VMAX values were calculated.
  • the dead time i.e., the elapsed time from the
  • the CS-S capability was displayed by performing sequential measurements of FI and FP on 5 min 1.2 ⁇ M FDA stained trapped cells, following their PBS rinsing
  • each CC was loaded with unstained (BPS free of substrate) ceUs and stained with one chosen substrate concentrations (in order to avoid possible
  • the level of FI at the beginning of the last rinse was higher than the level at the
  • Fig. 3d the cells were rinsed with FDA at concentration of 0.6, 1.2, 2.4 ⁇ M and
  • Lymphocytes activation is triggered by multiple interactions
  • plant derived proteins including phytohemagglutinin PHA, that bind
  • IFI intracellular fluorescence intensities
  • VMAX depends on the optoelelctronic
  • Peptidases and proteases play essential roles in protein activation, cell regulation
  • Typical peptidase substrates are short
  • peptidase is the cystein protease- Caspase which play a pivotal role in
  • AMC- and RllO-labeled peptidase substrates permit the detection of apoptosis
  • caspase-3 (CPP32/apopain), which has a substrate selectivity for the
  • PARP poly(ADP-ribose) polymerase
  • kinase protein kinase C and actin, is important for the initiation of apoptosis.
  • Both substrates can be used to continuously measure the activity of caspase-3.
  • Reactive oxygen species including singlet oxygen, superoxide, hydroxyl radical
  • ROOR' peroxides
  • ROOH hydroperoxides
  • NADH oxidizable cellular components
  • NADPH oxidizable cellular component
  • dopa oxidizable cellular components
  • Reactive oxygen species can also oxidize cholesterol and
  • leuco dyes also serve as fluorogenic
  • glucose oxidase The enzyme glucose oxidase is widely used for glucose determination. Glucose
  • Carbonic anhydrase catalyzes the reversible hydration of CO2 to carbonic acid.
  • Acetazolamide has been shown to bind carbonic anhydrases in a wide variety of
  • Fluorescent-labeled derivative of acetazolamide is used for
  • pre drug-treated cells are exposed to at least 2 different substrate
  • active material such as ,inducer, inhibitor,etc.
  • the drug-treated cells is determined.
  • Peripheral blood lymphocytes were loaded on a CC, and exposed to FDA, after
  • the determining parameter is the ratio between the initial and the final slopes-
  • lymphocytes to mild oxidative stress resulted in a lower rate of the second

Abstract

A process for measuring enzymatic activity in an identified, isolated, intact, single, viable cell. Each of the viable cells is placed within individual identified locations on a carrier of a cytometer having means to measure enzymatic activity of a single viable cell placed in an identified location. The identified isolated cell is exposed to a substrate of an enzyme to be measured, and the rate of product formed or released following every exposure of the cell to same or different concentrations of the substrate is measured. The isolated cell may be exposed to a sequence of at least two different concentrations of the substrate, and for each exposure the rate of product formed or released is measured. Figure (1) is a model of intracellular conversion of a substrate to a product.

Description

MEASUREMENTS OF ENZYMATIC ACTIVITY IN A SINGLE.
INDIVIDUAL CELL IN POPULATION
Field of the Invention
Enzymes are organic catalysts that cause and direct the numerous chemical
reactions that occur in living organisms. Most of chemical changes that occur in
hving cells are caused and controlled by enzymes. Assessing the enzyme activity
in a particular type of cells is therefore one of the principal approaches to the
study of what goes on in the same individual hving cells.
The present invention provides a new process and methodology for measuring
enzymatic activity in intact individual cells. More specifically, it provides the
capabilities for high precision enzymatic kinetic measurements of individual cells
under repeatable substrate exposure conditions. On-line reagent addition, and
controlling other changes in experimental conditions, can be easily accomplished,
and the dynamic changes in individual given cells is monitored in real-time.
Thus, the process of the invention provides a new valuable tool for assessing
enzymatic reaction kinetics, resulting in determination of activity of an
individual enzyme as well as of a series of different enzymes, in specific intact
cells under defined physiologic conditions. In a preferred embodiment of present invention, the substrate is either passively
or actively enters the cell, once inside, it is processed by the assessed intracellular
enzyme to generate detectable product.
In yet another preferred embodiment, the process of present invention is
applicable for measuring simultaneously the enzymatic activity in many
identified individual cells, within same population.
Since enzymes are ubiquitously involved in cellular function, the monitoring of
their reaction kinetics on the level of a single, individual cell may provide
valuable information. For example, in some human diseases, especially heritable
genetic disorders, there may be a deficiency or even a total absence of one or more
enzymes in the tissue. Moreover, measurements of the cellular activity of certain
enzymes are important in diagnosing diseases. Most enzymes can be poisoned or
inhibited by certain chemical reagents.
Numerous of drugs are designed to inhibit the excessive catalytic activity of
specific enzymes in abnormal conditions. Other drugs inhibit certain enzymes in
malfunctioning cells. The overall activity of such drugs can only be measured in
an intact system of the individual live cell.
An enzymatic activity is usually characterized by two parameters: VMAX - the
maximum enzyme production rate (velocity), of a product (P) out of a substrate (S)
at a saturation concentration of the latter, and KM - the Michaelis - Menten constant, which is reciprocally proportional to the enzyme affinity to the
substrate.
The relation between VMAX , KM, the substrate concentration [S] and the initial
velocity V, at which S converts to P, is given by the Michaelis - Menten equation:
V [s v M. AX κM +[sy
Unfortunately Eq. 1 is accurate only for a homogeneous medium in which the
following processes occur: .
[S] + [E] <-» [ES] and [ES] - [P] + [E] where [E] and [ES] are the enzyme
and the complex enzyme - substrate concentrations, correspondingly.
The determination of KM and VMAX, utilizing Eq. 1 calls for sequential exposures
and repeatable measurements of the same individual cell for various values of
[S\.
Unfortunately this requirement can not be achieved by the common cytometers:
The Flow Cytometer (FC) as well as the Laser Scanning Cytometer (LSC). The
FC enables the rapid measurement of the fluorescence intensity ( FI ) of a large
cell population. However because each cell in the flow is measured only once, the
kinetic curves of the FC
1. Dolbcare F, Fluorescent staining of enzymes for flow cytometry, Methods
Cell Biol 33:81-88, 1990
2. Klingel S, Rothe G, Kellerman W, Valet G, Flow cytometric determination
of serine proteinase activities in hving cells with rhodamine 110 substrates, .
Methods Cell Biol 41:449-460, 1994 3. Malin-Berdel J, Valet G, Flow cytometric determination of esterase and phosphatase activities and kinetics in hematopoietic cells with fiuorogenic substrates, Cytometry 1:222-228, 1980
4. Nooter K, Herweijer H, .Jonker RR, van den Engh GJ, On-line flow
cytometry. A versatile method for kinetic measurement, Methods Cell Biol
41:509-526, 1994
5. Turck JJ, Robinson JP, Leucine aminopeptidase activity by flow
cytometry, Methods Cell Biol 41:461-468, 1994
6. Watson JV, Dive C, Enzyme kinetics, Methods Cell Biol 41 :469-508, 1994]
provide sequential measurements of single cells over time but not of the same
single cell. Therefore, investigating different enzyme activities in different cell
types or in subcellular areas using the FC gives only an average KM value for a
population of cells or for specific enzymes in a cell-free system.
The LSC measures the fluorescence kinetic of individual cells under specific
conditions of low cell density in the selected field and of cell types and dyes which
do not suffer from fading, which disrupts the measurement [Watson JV, and Dive
C. Enzyme kinetics. Methods Cell Biol (1994) 41:469-508]. The LSC technique
cannot ensure the accurate rescarming of the same cell after repeatable staining
procedures since the cell may not have preserve its original location. Moreover,
the LSC cannot ensure preservation of the cell locations and thus cell
identification might be lost during repeatable rinsing and exposure to different
substrate concentrations. In order to provide the capabilities for kinetic measurement of individual cells
under repeatable staining conditions, a specially designed cytometer was used.
The cytometer (hereinafter referred to as Cellscan Mark S or CS-S) which, one of
its versions, was described in the US Patents 4,729,949, 5,272,081, 5,310,674 and
5,506,141 found to be applicable for measuring time resolved kinetics of
individual cells during cellular manipulation.
Using the unique apphcation of the CS-S, a new method was developed in which
the same cells are sequentially exposed to increasing substrate concentrations.
The product formation rate is measured for each cell at every substrate
concentration yielding a series of rates for the same individual cell. Using this
data, VMAX and apparent KMAPP (app = apparent) values can be calculated for
each ceU, giving the distribution of KMAPP and VMAX of the measured population
However, it should be emphasized that the process of present invention is not
limited to the CS-S cytometer and any cytometer comprising a microscope, light
detection means, a carrier to which cells are individually located, is within the
scope of the present invention.
Kinetic Analysis:
The kinetic parameters are derived by application of linear and nonlinear
modeling. The linear model y(t)=At+B seeks parameters A and B which fit the
data to a straight line equation, where y(t) is the measured quantity, t is the
time, and A and B are the calculated parameters. The CS-S algorithm uses χ2 as
the criteria for goodness-of-fit. a. Single Step Cell Staining;
A simplified model for the description of intracellular turnover of fluorogenic
substrate is presented in Fig. 1. First, the extracellular substrate [ L51 Jo permeates
into the cell, becoming [S]i - the intracellular substrate concentration. Then [S]i is
hydrolyzed or cleaved by enzymes to yield the intracellular (for example,
fluorescent) product [P]i, which may be released from the cell into the medium
and become [P]o .
As was previously shown [Bedner E, Melamed MR, Darzynkiewicz Z, Enzyme
kinetic reactions and fluorochrome uptake rates measured in individual cells by
laser scanning cytometry, Cytometry 33:1-9, 1998] the kinetics of [P]i can be
described, to a good approximation, by the rate equation :
(2) -^ ^ α - SIo -ZH L
Where α and β are the rates constants for the formation and leakage of the
intracellular fluorescein. It is important to emphasize that α represents two
processes: Permeation of S and its intracellular distribution as well as the
enzymatic hydrolysis of [S]i.
When solving Eq. 2, under the initial condition of one step staining, [P(t=0)]ι = 0
it is easily shown that
(3)
Figure imgf000007_0001
b. Sequential staining:
Another aspect of present invention relates to sequential exposures of the same
individual cells to different substrate concentrations. This differs from the above
case by the fact that at the starting time point of staining, with a given solution,
cells are already being stained to a level of:
Figure imgf000008_0001
τ stands for the time point of terminating the staining with a given substrate
concentration, say M times [S\ (M[S]), and initiation of staining with different
substrate concentration, say N[S\.
Now, it is possible to solve Eq.2 under the initial conditions presented by Eq. 4.
By separation of variables and integration over [P]i between the concentration
limits [P(τ)]i and [P(t)]ι; and integration over time between the time points 0
(when staining solutions are being replaced) and t, one gets:
(a
Figure imgf000008_0002
Converting the logarithmic expression into exponential one and introducing
[F(τ)]ι of Eq.4 into Eq.5 yields:
(6)
F (0] = — M
Figure imgf000009_0001
When single step staining is performed (starting of unstained cell, M=0), only the
last term of Eq. 6 remains, which is consistent with Eq. 3.
As long as the expression exp(-βt) s 1-βt holds for the duration of the observation
interval of the individual cells in given conditions, regardless of their staining
history, each of the exponential terms in Eq. 6 can be replaced, without losing
accuracy, by its first two terms of the power series. Hence, Eq. 6 may be linearly
approximated to give:
(7)
d[F{t
t > τ a[SY (Mτ + Nt) [F(t)]T ^ Λ dt Eq. 7 should be interpreted as follows: for 0< t<τ, staining proceeds according to
[P(t)]i = [S]Mt. After replacing the staining solution M by N at time t=τ, the
staining due to M[S] remain constant [P(τ)]ι = [S]Mτ, While that due to N
increases at a rate of [S N, namely solely depending on the concentration in use.
Simulations of several practical staining protocols, based on Eq.7, are
graphically presented in Fig. 2 and briefly described in the following:
a) Rinsing the cells with a staining solution [N] that maintains [N] = [M, results
in a staining curve [P(t)]ι=α[S]iV[τ+t]. At the observation time τ+t [P]i had a
production rate of α[S]iV, the same rate as that of a[S\M prior to τ+t (Fig. 2a).
b) Rinsing the cells with PBS alone washed away [M\ residues leaving the
staining solution at a concentration [M\ = 0. This action halted any further
production [P]ι (since α[S]iV = 0 at the time of application i) hence [P]i line
remained parallel to the time axis for the duration of the observation t. (Fig. 2b).
c) In a similar way, the cells were rinsed with a staining solution [N\ ≠ [M\ that
washed away [M\ and left the staining solution at a concentration [N]. The
production rate of [P]i, as expected, changed to α N [S] for the observation
duration t. (Fig. 2c )
d) The last experiment, was a combination of b) and c) in succession. First the
cells were rinsed at time ti with PBS and that halted the production of Fi. The
next stage was to rinse with a staining solution [N] ≠ [M\ replacing the PBS with
a solution of concentration [N\. The production rate then changed to α[S]iVfor the
for the observation duration t. (Fig. 2d). Finally, the determination of Δt, the overall sequential staining experiment
procedure time duration, was restricted to follow the present CS-S Standard
deviation in performing individual cell FI measurements, which is < 2%.
In order not to exceed this value when linearly approximating the exponential
terms, a Δt value which keeps the ratio
exp(-βΔt)/(l-βΔt) = 2% is sought. Hence, introducing β = 10-4 sec-1, which is the
outcome of many hundreds of independent experiments (data not shown), yields
Δt ≥ 103 sec.
Summary of the Invention
It is an object of present invention to provide a process for measurement and
characterization of intra- and extra-cellular enzymatic activity taking place in the
same identified individual cell, in a population of cells, following its incubation
with different concentrations of a substrate. The substrate should be a substance
that yields a product that is detectable by physical means, such as changes in
fluorescence intensity, color intensity, radioactive radiation, etc.
It is a further object of present invention to establish a new method for the
determination of KMAPP and VMAX values for enzymatic reactions carried out
inside an identified individual cell. It is an additional object of the present
invention to determine kinetic values of extracellular enzymes, released from an
individual cell. It is yet an additional object of present invention to provide a tool
for measuring differences in kinetic enzymatic activity in the individual cell
following various treatments of same cell with biologically active materials. A further object of present invention is to provide a process for measuring
simultaneously the enzymatic activity in many identified individual cells, within
same population.
Brief Description of the Drawings
Fig. 1: A model of intracellular conversion of a substrate to a product. [S]o, [S]i
are the extracellular and intracellular substrate concentrations and [P]o, [P]ι are
the extracellular and intracellular product concentrations. [E] and [ES] are the
enzyme and enzyme substrate complex concentrations, ki is the rate constant for
formation of the complex [ES], k-i is the rate constant for the reversed reaction
and k2 is the rate constant for product formation.
Fig. 2: Simulation of an individual cell sequential FI time dependency following
several exposure procedures to substrate concentration. M = multiplication
coefficients of initial substrate concentration.
R = rinsing at a given time point. Panels: a - rinsing with the same concentration
yields identical slopes, b - sequential rinsing with (yield identical slopes as in
panel a) and without (zero slopes) substrate, c - sequential rinsing with
increasing substrate concentrations, d - sequential rinsing with increasing
substrate concentrations while in between rinsing without substrate.
Fig. 3: Experimental results of individual cells sequential staining procedure. The
numbers in the boxes are the slopes of FI(t) (initial velocities), given in arbitrary
intensity units per second. The experiment follows the simulation shown in Fig.
2.
Fig. 4: Complete sequential staining procedure of numerous cells. Each of the four clusters contains 13 lines. Each line defined by six FI measurements taken
in six different time points for the same individual cell when exposed to the
relevant substrate concentration. Ri to R4 - the space between clusters stands for
replacement duration of the staining solutions (0.6, 1.2, .4 and 3.6.μM). The
solid line in each of the four clusters is sketched for clarification purposes. It
indicates the increasing slopes of one chosen set of sequential exposure of one
individual cell.
Fig. 5: Individual KMAPP and VMAX for two representative cells and their Pearson
correlation coefficient ( 2).
Fig. 6: The distribution of individual KMAPP (6A) and VMAX (6B) for cells that were
incubated with ( — ) and without (- - - ) PHA.
Fig. 7: Rate of change of FI before and after exposure of an individual cell to
hydrogen peroxide (H2O2) compared with control. The ratio pre to post treatment
slopes in control cells is double that of cells exposed to H2O2 (treated).
The following examples are provided merely to illustrate the invention and are
not intended to limit the scope of the invention in any manner.
Examples
Example 1. Measuring intracellular nonspecific esterase activity in a single
lymphocyte using fluorescein-diacetate (FDA) as the substrate. Materials and Methods
Phytohemagglutinin PHA (HA15, Murex Biotech ) was reconstituted in 5 ml of
double-distilled water and further diluted ten times. For stimulation, lOμl of this
solution was added to a 90 μl cell suspension (7xl06 cells/ml).
The culture medium consisted of RPMI-1640 (Biological Industries),
supplemented with 10% (v/v) heat-inactivated fetal calf serum (Biological
Industries), 2mM L-glutamine, 10 mM Hepes buffer solution, ImM sodium
pyruvate, 50 U/ml penicillin and 50Units/ml streptomycin.
A staining solution of 3.6 μM FDA (Riedel-de Haen Ag. Seelze-Hanover) in
Dulbecco Phosphate Buffered Saline (PBS, Biological Industries) was prepared as
follows: 50 mg of FDA was dissolved in 5 ml of DMSO (Sigma). 7.5 μl of this
solution was added to 50 ml PBS. For 0.6, 1.2 and 2.4μM the solution was further
diluted in PBS.
Preparation of Peripheral Blood Mononuclear Cells (PBMC :
30 Heparinized blood (30 ml), was taken from healthy, normal volunteers. The
procedure for separating the PBMC has been described in detail, elsewhere
[Sunray M, Deutsch M, Kaufman M, Tirosh R, Weinreb A, and Rachmani H. Cell
Activation influences cell staining kinetics, Spectrochimica Acta A (1997)
53:1645-1653]. Shortly after removing the iron absorbing cells, the remaining
cells are layered on a two-layer (100% and 80%) cell density gradient (Ficoll
Paque, Pharmacia 1.077 g/ml) and centrifuged. The cells accumulated at the interface between the two Ficoll layers, were collected and kept at 37° C in 5 ml
of enriched culture medium overnight. The next day the PBMC were washed and
resuspended in PBS at a final concentration of 7-106 cells/ml. More than 70% of
the cells were defined as T lymphocytes and viability, which was determined
using eosin, was always higher than 90%.
Activation of PBMC by PHA:
Freshly prepared PBMC (7-106 cells/ml) were incubated at 37°C, 5% C02 with 5
μgr/ml PHA for 30 minutes. PBMC controls were incubated without PHA under
identical conditions.
The CS-S Apparatus
The multiparametric, computerized, discrete cytometer CS-S used in performing
this example was described in detail in the above specified US Patents. Its
central feature is a cell carrier (CC) incorporating a 100 x 100 dimensional array
having a conical cross-section with an upper opening of ~7μm and lower opening
of ~4μm, each approximately 20μm apart, in which individual cells are trapped.
The cell carrier is mounted on a computer-controlled stage that enables repeated
multi-scanning of the same cells.
Cells were irradiated with 1-10 μW of 442 nm light from a He-Cd laser. Under
the staining conditions used here, the scanning time for obtaining a 'count of
10,000 photons in order to have statistical photonic error of ~1% from each,
7 dye-loaded cell varied from 0.001 sec to approximately 0.5 sec. The acquired data, including cell position, measurement duration for each cell,
absolute time, intensity at two different wavelengths, computed fluorescence
polarization values and test set-up information, are displayed on the screen,
on-line, graphically and numerically, and stored in the memory. Software
enables the determination of the range and other statistical characteristics of all
parameters, for either the entire cell population, or an operator-selected
sub -population, or an individual cell, before, or during the scan.
Cell Loading
Loading the cells in wells traps on the Cell Carrier (CC) was carried out, as
described in Deutsch M, and Weinreb A., Apparatus for High Precision Repetitive
Sequential Optical Measurement of Living Cells, Cytometry (1994) 16: 214-226.
An ahquot of 80 μl of unstained cell suspension (7x106 cells/ml) was loaded on the
CC. Initial scanning was then performed in order to detect individual cell
background scattering and auto-fluorescence. This undesired signal is recorded
per measurement location and subtracted from the total emission signal (after
exposure) in order to obtain the correct fluorescence signal.
Cell Staining and Kinetic Measurement:
For fluorescence intensity FI(t) measurements, trapped cells on the CC were
sequentially exposed to increasing concentrations of FDA in PBS staining
solutions.
Following background measurement, the volume of PBS, which covers the cells,
was pumped out and the following procedure was carried out: At time point zero, 40 μl of the lowest substrate concentration solution was
applied on top of the trapped cells and a pre-chosen cell field was sequentially
scanned 6 times. This yielded 6 accurately timed FI data points per each
individual cell at a given dye concentration. FI is usually measured utihzing
epi-fluoesceiice optical arrangement which permits the differentiation between
the excitation energy and the emitted fluorescence energy to be detected by
photomultipliers, CCD detectors etc.
The above procedure is repeated for each different substrate solution used in the
experiment.
This yielded six FI data points for each individual cell, per substrate
concentration, from which V was extracted and the individual cell KMAPP and
VMAX values were calculated. The dead time, i.e., the elapsed time from the
addition of a staining solution to the beginning of the measurement, which is
monitored by the computer, is about 7-15 sec.
Results
Repeatability runs:
The experimental arrangement of the new process calls for high-level
performance in terms of repeatabihty and accuracy in periodical measurements of
individual cells.
The CS-S capability was displayed by performing sequential measurements of FI and FP on 5 min 1.2μM FDA stained trapped cells, following their PBS rinsing
out of excess substrate solution and , possible extra-cellular Pi (at this stage,
constancy of FI is expected due to staining termination and negligibihty of Pi
leakage).
The individual cell coefficient of variance (CV) obtained in more then 10
successive measurement scans of a 10 x 10 cell field, never exceeded 2% for FI.
Fading was not noticeable.
Accuracy Runs:
Accurate intensity measurement capabilities and specific monitoring of
alterations in Fi production rate are mandatory for the present process. This was
first serially examined by measuring FI of the CC loaded with cell-free
fluorescein solutions at concentrations of 0.6, 1.2 and 2.4μM, five times each,
while rinsing with PBS between concentrations.
The ratios, FI([s]i)/FI([s]j), between the measured FI, for different [s] and
fluorescein concentrations, were found to be in correlation to the ratios of FDA
substrate concentrations (fs]ι/[s]j) and free fluorescein concentrations ([F]i/[F]j),
(see Table 1).
The correlation between the substrate concentration (FDA concentration) and the
measured staining rates by intracellular fluorescein was established for cells.
First, each CC was loaded with unstained (BPS free of substrate) ceUs and stained with one chosen substrate concentrations (in order to avoid possible
influences of additive staining when sequential exposure is performed).
Second the sequential staining manipulation was examined. As can be seen in
the third and forth column of Table 1, there was good correlation between the
increasing staining rates (which means increasing rate of product formed) and
the increasing substrate concentrations in both cases.
Next, using the sequential staining manipulation [adding in sequence of different
concentrations of substrate and measuring the production rate of F in between
additions, by monitoring FI(t)] with cells, it was verified the theory described in
equation 7 specifically for the four cases that are detailed above and are
presented as simulations in Fig. 2.
First, cells were loaded on the CC and stained with FDA. Re-washing the cells
after every five or six scans with the same FDA concentration gave similar slopes
after every wash as can be seen for FDA at 1.5μM in Fig. 3a.
Rinsing (R) the cells with FDA and with PBS (no FDA, N=0, equation 7)
alternately gave similar slopes when FDA was present and almost zero slope
when FDA was absent, as shown in Fig 3b.
The level of FI at the beginning of the last rinse was higher than the level at the
end of the rinse with PBS though the slopes (velocities which are the magnitude
used for KMAPP determination) were identical. This difference is probably due to
technical reasons such as a slight change in the focus while manipulating FDA concentration or by laser beam geometrical instability etc. In Fig. 3c the cells
were rinsed with increasing FDA concentration of 0.6, 1.2, 2.4 and 3.6μM.
In Fig. 3d, the cells were rinsed with FDA at concentration of 0.6, 1.2, 2.4 μM and
in between with PBS without FDA. The PBS gave almost zero slopes (no
production of FI) while the increasing FI slopes were in good correlation with the
increasing FDA concentration. Generally, as can be seen from figures 2 and 3,
there was good correlation between the theoretical simulation and results of the
experiments.
Table 1
Figure imgf000020_0001
Table 1: Ratios of substrate concentrations (a); of fluorescein solutions FI (b); and
of intracellular fluorescein production rates of trapped cells: (c) parallely exposed
on different CC each to different FDA concentrations and (d) sequentially exposed
to different FDA concentrations on the same CC. Determination of Individual KMAPP and VMAX Values:
Determination of KMAPP and VMAX was carried out by utihzing the reciprocal of
Eq. 8 (Lineweaver - Burk plot)
Figure imgf000021_0001
Thus, the use of two substrate concentrations should be, in principal, enough for
the extraction of KM and VMAX . Minimization of possible experimental errors,
while restricted by the linear range of time duration, Δt ≤ 103 sec, led to the
choice of 4 FDA concentrations: 0.6, 1.2, 2.4 and 3.6 μM. Practically, trapped cells
on the cell carrier were sequentially exposed to the four FDA concentrations
staining solutions and scanned for determination of released fluorescein six
times per the same FDA concentration. A representative chart of a complete
measurement procedure made on 50 cells is shown in Fig. 4.
A plot of Eq. 8 for two cells out of the measured population of Fig. 4 is presented
in Fig. 5.
Example 2.
Utilization of Individual KMAPP Measurements
The Influence of Mitogenic Stimulation upon KMAPP and VMAX The activation of lymphocytes is a critical stage in most immune responses and
allows these cells to exert their specific functional capabilities. During activation,
the resting lymphocytes undergo complex changes resulting in cell differentiation
and proliferation. Lymphocytes activation is triggered by multiple interactions
that occur at the cell surface, which initiate intracellular biochemical events
within the cell that culminate in cellular response.
One of the experimental models used to study lymphocytes activation is lectins,
plant derived proteins (including phytohemagglutinin PHA), that bind
carbohydrate groups at the cell surface and stimulate relevant receptors involved
in physiologic lymphocyte activation. Many pharmacological agents mimic or
inhibit some of the intracellular events associated with T cell activation. An
example is described herein for individual KMAPP measurement following
lymphocyte activation.
The sequential FDA hydrolysis experiment was executed fohowing incubation of
cells with and without phytohemagglutinin PHA. The distribution of individual
KMAPP and VMAX values for both cases are presented in Fig. 6a and 6b,
respectively. The average KMAPP and VMAX were found to be 4.88 μM and 1.50 μM
and 695 (intensity/sec) and 652 (intensity/sec), indicating a decrease of 69% in
KMAPP and 6% in VMAX values for PHA compared to the control. Both distributions
indicated cell heterogeneity having a CV of about 70%. For comparison purposes, at the average level, the FC (Beckton-Dickinson
FACSCalibur) was used to determine KMAPP and VMAX value averages taken over
the cell population following the protocol suggested by Watson, JV and Dive, C,
Enzyme Kinetics. Methods Cell Biol (1994) 41: 469-508. Four means of
intracellular fluorescence intensities (IFI) were calculated from data accumulated
along four time gates of 25 second each and 30 seconds apart, from which Vo was
extracted. This process was sequentially performed on five different aliquots of
cells (50 μl, at a concentration o '6x106 cells/ml) each exposed to different FDA
concentrations (0.3, 0.6, 1.2, 1.8 and 2.4 μM). Introducing these average Vo in
values Eq. 8 yielded population average KMAPP and VMAX of 2.16μM and 4.32μM
and 6.6 and 5.83 in cells incubated with and without PHA. It should be noted
that while KMAPP is an intrinsic value, VMAX depends on the optoelelctronic
arrangement under use. Thus, obviously, at the population level, measurements
carried out both on FC and average calculated from individual cell KMAPP
measurement data yield similar KMAPP values, indicating the validity of the
invented methodology.
Example 3.
Using basicaUy the same procedure, it is possible to determine the fohowing
enzymes activity in the single, individual cell:
1. Proteases and Peptidases
Peptidases and proteases play essential roles in protein activation, cell regulation
and signaling, as well as in the generation of amino acids for protein synthesis or
utilization in other metabohc pathways. Typical peptidase substrates are short
peptides conjugated to fluorophores (like 7-Amino-4-methylcoumarin (AMC) or Rhodamine 110). In the presence of the enzyme, the fluorogenic part is released,
and may be easily determined by fluorescence measurements. One example of
peptidase is the cystein protease- Caspase which play a pivotal role in
programmed cell death.
AMC- and RllO-labeled peptidase substrates, permit the detection of apoptosis
by assaying for increases in caspase-3 and caspase-3— like protease activities. The
activation of caspase-3 (CPP32/apopain), which has a substrate selectivity for the
amino acid sequence Asp-Glu-Val-Asp (DEVD) and cleaves a number of different
proteins, including poly(ADP-ribose) polymerase (PARP), DNA-dependent protein
kinase, protein kinase C and actin, is important for the initiation of apoptosis.
Both substrates can be used to continuously measure the activity of caspase-3.
2. Peroxidases
Reactive oxygen species, including singlet oxygen, superoxide, hydroxyl radical
and various peroxides (ROOR') and hydroperoxides (ROOH).are produced during
a number of physiological processes. Activated oxygen species react with a large
variety of easily oxidizable cellular components, including NADH, NADPH, dopa,
ascorbic acid, histidine, tryptophan, tyrosine, cysteine, glutathione, proteins and
nucleic acids. Reactive oxygen species can also oxidize cholesterol and
unsaturated fatty acids, causing membrane lipid peroxidation. The importance of
the nitric oxide radical enzyme producer and other reactive oxygen species as
biological messengers has been increasingly recognized during the last several
years. Assaying of oxidative activity in hve cells can be done by using Leuco
Dyes. Fluorescein, rhodamine and various other dyes can be chemically reduced to colorless, non-fluorescent leuco dyes. These "dihydro" derivatives are readily
oxidized back to the parent dye by some reactive oxygen species and thus can
serve as fluorogenic probes for detecting oxidative activity in cells.
Dihydroethidium, chcMorodihydrofluorescein (H2DCF) and dihydrorhodamine
123 react with intracellular hydrogen peroxide — a reaction mediated by
peroxidase, cytochrome C or Fe2+. The leuco dyes also serve as fluorogenic
substrates for peroxidase enzymes.
3. Glucose Oxidase
The enzyme glucose oxidase is widely used for glucose determination. Glucose
oxidase reacts with glucose to form gluconolactone and H2O2. The H2O2 is then
detected using fluorescent probe as described above.
4. Carbonic Anhydrase
Carbonic anhydrase catalyzes the reversible hydration of CO2 to carbonic acid.
Acetazolamide has been shown to bind carbonic anhydrases in a wide variety of
eukaryotic cells. Fluorescent-labeled derivative of acetazolamide is used for
studying carbonic anhydrase activity in live cells.
As was described hereinabove, a major embodiment of present invention involves
the measurement in individual cells of KMAPP and VMAX values of particular
cellular enzymes. This is a rather important assay relating to drug activity within a single intact cell.
In general, pre drug-treated cells are exposed to at least 2 different substrate
concentrations in order to determine the enzymatic KMAPP and VMAX values. The same cells are then exposed to the investigated drug (or any other biologically
active material, such as ,inducer, inhibitor,etc.), during a selected period of time.
Finally, the cells are again exposed either to the same 2 substrate concentrations
or another 2 or more substrate concentrations, and the KMAPP and VMAX values of
the drug-treated cells, is determined.
In the following, an example is given in order to demonstrate this principle.
Peripheral blood lymphocytes were loaded on a CC, and exposed to FDA, after
which individual FI(t) was measured. The same trapped cells, on the same CC
were then rinsed (R) twice with fresh buffer and incubated at 37°C in the
presence_of hydrogen peroxide (an apoptotic inducer). At the end of incubation,
the same cells were again exposed to the same FDA concentration and FI(t)
measurements were again performed.
Despite the fact that such an experimental procedure is self consistent (since it
has its own control on an individual cell basis, namely control measurements of
KMAPP and VMAX of ceUs, prior to their incubation with the drug), an additional
experiment was carried out as a second external control, but this time cells were
incubated without the drug.
FI(t) of two representative cells, measured prior to and after incubation with
(treated) and without (control) hydrogen peroxide (the drug) are shown in Fig. 7.
Since cells are in general heterogeneous, one would expect a distribution of FI(t)
rates (slopes) in the same experiment. This is why the initial slopes (Vo) of the two curves in Fig. 7 are not identical. Thus, in such an experimental procedure,
the determining parameter is the ratio between the initial and the final slopes-,
namely, the ratios between FI(t) slopes prior to and after incubation (with and
without drugs), as well as ratios of individual KMAPP and VMAX prior to and after
incubation.
Calculation of both slope ratios shown in Fig. 7 indicates that exposure of
lymphocytes to mild oxidative stress resulted in a lower rate of the second
staining reaction, in comparison to control. The ratio between the first and the
second reactions reflected the apoptotic activity of the inducer Moreover, it can
provide an idea regarding apoptotic resistance of specific individual cells.

Claims

1. A process for measuring enzymatic activity in an identified, isolated, intact,
single, viable cell, comprising the steps:
(a) placing each of the viable cells within individual identified locations on a
carrier of a cytometer having means to measure enzymatic activity of a single
viable cell placed in an identified location,
(b) exposing the identified isolated cell to a substrate of an enzyme to be
measured, and
(c) measuring the rate of product formed or released following every exposure of
the cell to same or different concentrations of the substrate.
2. A process according to claim 1, wherein the isolated cell is exposed to a
sequence of at least two different concentrations of the substrate and for each
exposure the rate of product formed or released, is measured.
3. A process according to claim 2 for measuring the kinetic of a particular
enzyme, wherein initial rate production (Vo-velocities) are measured from which
VMAX and KM are calculated.
4. A process according to claim 1, wherein activities of several different enzymes
are measured in the same isolated cell in a population..
5. A process according to claim 1, wherein activity of a particular enzyme is
measured before and after the treatment of said isolated cell with a biologicaUy
active material.
6. A process according to claim 5, wherein the biologically active material is a
drug.
7. A process according to claim 5, wherein the biologicaUy active material is an
inhibitor of any of the treated cell's functions.
8. A process according to claim 5, wherein the biologically active material
stimulates, induces or promotes a particular function or property of the treated
cell.
9. A process according to claim 5, wherein the production rates (Vo) are
measured and VMAX and KM are calculated before and after ceU treatments.
10. A process according to claim 1, wherein the substrate consists of a known
fluorescent substance that as a result of enzymatic activity is converted into a
measurable fluorescentic product.
11. A process according to claim 10, wherein the substrate is fluorescein- diacetate (FDA).
12. A process according to claim 1, wherein the measured activity is of an
intra-cellular enzyme.
13. A process according to claim 12, wherein the intra-cellular enzyme is selected
from the group comprising esterase, protease, peptidase, peroxidase, glucose
oxidase and carbonic anhydrase.
14. A process according to claim 1, wherein the measured activity is of an
extra-cellular enzyme.
15. A process according to claim 1 wherein the isolated single cell is a
lymphocyte.
16. A process according to claim 1, wherein the isolated single cell is a
lymphocyte, the enzyme is an esterase and the substrate is fluorescein-diacetate.
17. A process according to claim 1, wherein the substrate is color-less and the
product formed or released is colored.
18. A process according to claim 1, wherein the substrate is colored and the
product formed or released is colorless.
PCT/IL2001/000443 2000-05-18 2001-05-17 Measurements of enzymatic activity in a single, individual cell in population WO2001088176A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US10/276,080 US20030211458A1 (en) 2000-05-18 2001-05-17 Measurements of enzymatic activity in a single, individual cell in population
EP01934272A EP1287160A4 (en) 2000-05-18 2001-05-17 Measurements of enzymatic activity in a single, individual cell in population
JP2001584558A JP2003533209A (en) 2000-05-18 2001-05-17 Method for measuring enzymatic activity of individual single cells during cell population
AU60565/01A AU6056501A (en) 2000-05-18 2001-05-17 Measurements of enzymatic activity in a single, individual cell in population

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL13623200A IL136232A0 (en) 2000-05-18 2000-05-18 Measurements of enzymatic activity in a single, individual cell in population
IL136232 2000-05-18

Publications (2)

Publication Number Publication Date
WO2001088176A2 true WO2001088176A2 (en) 2001-11-22
WO2001088176A3 WO2001088176A3 (en) 2002-04-11

Family

ID=11074140

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2001/000443 WO2001088176A2 (en) 2000-05-18 2001-05-17 Measurements of enzymatic activity in a single, individual cell in population

Country Status (6)

Country Link
US (1) US20030211458A1 (en)
EP (1) EP1287160A4 (en)
JP (1) JP2003533209A (en)
AU (1) AU6056501A (en)
IL (1) IL136232A0 (en)
WO (1) WO2001088176A2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7403647B2 (en) 2004-09-13 2008-07-22 Seng Enterprises Ltd. Method for identifying an image of a well in an image of a well-bearing component
US7405071B2 (en) 2003-02-27 2008-07-29 Seng Enterprises Ltd. Method and device for manipulating individual small objects
US7888110B2 (en) 2003-06-26 2011-02-15 Seng Enterprises Ltd. Pico liter well holding device and method of making the same
US8409509B2 (en) 2007-04-12 2013-04-02 Regents Of The University Of Minnesota Systems and methods for analyzing a particulate
US9739699B2 (en) 2007-11-15 2017-08-22 Seng Enterprises Ltd. Device for the study of living cells
US9975118B2 (en) 2007-11-15 2018-05-22 Seng Enterprises Ltd. Device for the study of living cells
US10190082B2 (en) 2003-06-26 2019-01-29 Seng Enterprises Ltd. Multiwell plate

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003034502A1 (en) * 2001-10-11 2003-04-24 Koninklijke Philips Electronics N.V. Thin film transistor device and method of manufacturing same
US8597597B2 (en) 2003-06-26 2013-12-03 Seng Enterprises Ltd. Picoliter well holding device and method of making the same
WO2005008626A1 (en) * 2003-07-11 2005-01-27 University Of North Carolina At Chapel Hill Methods and systems for controlling a computer using a video image and for combining the video image with a computer desktop
US20050064524A1 (en) * 2003-08-11 2005-03-24 Mordechai Deutsch Population of cells utilizable for substance detection and methods and devices using same
JP2007520546A (en) * 2004-02-03 2007-07-26 ケマジス リミティド A stable amorphous form of Montelukast sodium
WO2006003664A1 (en) * 2004-07-07 2006-01-12 Seng Enterprises Ltd. Method and device for identifying an image of a well in an image of a well-bearing component
WO2006080000A1 (en) 2005-01-25 2006-08-03 Seng Enterprises Ltd. Device for the studying individual cells
DE102005034043B4 (en) * 2005-07-18 2019-12-12 Südzucker Aktiengesellschaft Mannheim/Ochsenfurt Mixture containing L-carnitine and trehalulose and product containing the mixture
WO2007052245A1 (en) 2005-11-03 2007-05-10 Seng Enterprises Ltd. Method and device for studying floating, living cells
US20060223999A1 (en) * 2006-05-10 2006-10-05 Chemagis Ltd. Process for preparing montelukast and precursors thereof
US7629125B2 (en) 2006-11-16 2009-12-08 General Electric Company Sequential analysis of biological samples
US8305579B2 (en) 2006-11-16 2012-11-06 Thomas Pirrie Treynor Sequential analysis of biological samples
US9201063B2 (en) 2006-11-16 2015-12-01 General Electric Company Sequential analysis of biological samples
WO2009105481A1 (en) * 2008-02-19 2009-08-27 The Buck Institute For Age Research Mao-b elevation as an early parkinson's disease biomarker
US9677125B2 (en) * 2009-10-21 2017-06-13 General Electric Company Detection of plurality of targets in biological samples

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5905031A (en) * 1995-05-18 1999-05-18 Coulter International Corp. Identification of blast cells in a leukocyte cell preparation

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4308351A (en) * 1980-04-18 1981-12-29 Joseph Leighton System for growing tissue cultures
IL68507A (en) * 1982-05-10 1986-01-31 Univ Bar Ilan System and methods for cell selection
US5310674A (en) * 1982-05-10 1994-05-10 Bar-Ilan University Apertured cell carrier
US5272081A (en) * 1982-05-10 1993-12-21 Bar-Ilan University System and methods for cell selection
US5681718A (en) * 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
JP2662215B2 (en) * 1986-11-19 1997-10-08 株式会社日立製作所 Cell holding device
GB2233928B (en) * 1989-05-23 1992-12-23 Brother Ind Ltd Apparatus and method for forming three-dimensional article
US5635386A (en) * 1989-06-15 1997-06-03 The Regents Of The University Of Michigan Methods for regulating the specific lineages of cells produced in a human hematopoietic cell culture
GB8927742D0 (en) * 1989-12-07 1990-02-07 Diatec A S Process and apparatus
US5204055A (en) * 1989-12-08 1993-04-20 Massachusetts Institute Of Technology Three-dimensional printing techniques
US5650323A (en) * 1991-06-26 1997-07-22 Costar Corporation System for growing and manipulating tissue cultures using 96-well format equipment
GB9215834D0 (en) * 1992-07-24 1992-09-09 Celltech Ltd Cell culture
US5395588A (en) * 1992-12-14 1995-03-07 Becton Dickinson And Company Control of flow cytometer having vacuum fluidics
US6206672B1 (en) * 1994-03-31 2001-03-27 Edward P. Grenda Apparatus of fabricating 3 dimensional objects by means of electrophotography, ionography or a similar process
US5707869A (en) * 1994-06-28 1998-01-13 Wolf; Martin L. Compartmentalized multiple well tissue culture plate
US5824536A (en) * 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
US5627045A (en) * 1995-04-12 1997-05-06 Biolog, Inc. Multi-test format with gel-forming matrix for characterization of microorganisms
US6117612A (en) * 1995-04-24 2000-09-12 Regents Of The University Of Michigan Stereolithography resin for rapid prototyping of ceramics and metals
US5840565A (en) * 1995-08-22 1998-11-24 The Regents Of The University Of California Methods for enhancing the production of viral vaccines in PKR-deficient cell culture
US6043092A (en) * 1996-03-18 2000-03-28 University Of Pittsburgh Cell culture media for mammalian cells
US6103479A (en) * 1996-05-30 2000-08-15 Cellomics, Inc. Miniaturized cell array methods and apparatus for cell-based screening
US6046426A (en) * 1996-07-08 2000-04-04 Sandia Corporation Method and system for producing complex-shape objects
US5854684A (en) * 1996-09-26 1998-12-29 Sarnoff Corporation Massively parallel detection
US6692961B1 (en) * 1996-10-11 2004-02-17 Invitrogen Corporation Defined systems for epithelial cell culture and use thereof
US6627426B2 (en) * 1997-02-14 2003-09-30 Invitrogen Corporation Methods for reducing adventitious agents and toxins and cell culture reagents produced thereby
US6383810B2 (en) * 1997-02-14 2002-05-07 Invitrogen Corporation Dry powder cells and cell culture reagents and methods of production thereof
US6007228A (en) * 1997-05-21 1999-12-28 Neomagic Corp. Master digital mixer with digital-audio links to external audio in a docking station and to internal audio inside a portable PC
KR100266448B1 (en) * 1997-06-26 2000-09-15 박종헌 Mass production of taxol by changing temperature during the plant cell culture
US6066285A (en) * 1997-12-12 2000-05-23 University Of Florida Solid freeform fabrication using power deposition
US6210910B1 (en) * 1998-03-02 2001-04-03 Trustees Of Tufts College Optical fiber biosensor array comprising cell populations confined to microcavities
US6378527B1 (en) * 1998-04-08 2002-04-30 Chondros, Inc. Cell-culture and polymer constructs
US6528286B1 (en) * 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
FR2779443B1 (en) * 1998-06-08 2000-08-04 Claude Hanni ORGANIC CELL CULTURE AND STUDY OF THEIR ELECTROPHYSIOLOGICAL ACTIVITY AND MEMBRANE DEVICE USED IN SUCH A DEVICE
AT407047B (en) * 1998-08-03 2000-11-27 Pfaller Walter Dr CELL CULTURE DEVICE
KR100271208B1 (en) * 1998-08-13 2000-12-01 윤덕용 Selective infiltration manufacturing method and apparatus
US6511430B1 (en) * 1998-08-19 2003-01-28 University Health Network Use of high frequency ultrasound imaging to detect and monitor the process of apoptosis in living tissues, ex-vivo tissues and cell-culture
US6342384B1 (en) * 1998-08-21 2002-01-29 The University Of Va Patent Foundation Production of adenoviral vectors using serum-free suspension cell culture in a hollow fiber system
DE29817223U1 (en) * 1998-09-24 1998-11-19 Marotzki Stefan Dr Device for taking up a cell culture
US6228437B1 (en) * 1998-12-24 2001-05-08 United Technologies Corporation Method for modifying the properties of a freeform fabricated part
US6492148B1 (en) * 1999-03-05 2002-12-10 Akzo Nobel Nv Genetically engineered cell culture adapted infectious bursal disease virus (IBDV) mutants
US6455310B1 (en) * 1999-03-23 2002-09-24 Biocrystal Ltd. Cell culture apparatus and method for culturing cells
US6410309B1 (en) * 1999-03-23 2002-06-25 Biocrystal Ltd Cell culture apparatus and methods of use
JP4543131B2 (en) * 1999-04-26 2010-09-15 ジェネンテック, インコーポレイテッド Cell culture methods for glycoproteins
US6338964B1 (en) * 1999-05-07 2002-01-15 Bayer Corporation Process and medium for mammalian cell culture under low dissolved carbon dioxide concentration
US6372494B1 (en) * 1999-05-14 2002-04-16 Advanced Tissue Sciences, Inc. Methods of making conditioned cell culture medium compositions
AU5444800A (en) * 1999-05-27 2000-12-18 Research Foundation Of State University Of New York, The LTiGTin vitroLT/iGT cell culture device including cartilage and methods of usingthe same
JP2001037472A (en) * 1999-07-28 2001-02-13 Bio Quest:Kk Three dimensional cell-culturing base medium and cell culture using the same
US6333192B1 (en) * 1999-08-09 2001-12-25 North Carolina State University Method of producing an undifferentiated avian cell culture using avian primordial germ cells
NZ529329A (en) * 1999-08-25 2005-06-24 Immunex Corp Compositions and methods for improved cell culture
US6649408B2 (en) * 2000-03-24 2003-11-18 George Mason University Microdroplet cell culture technique
CA2307404A1 (en) * 2000-05-02 2001-11-02 Provenance Systems Inc. Computer readable electronic records automated classification system
KR20010110945A (en) * 2000-06-09 2001-12-15 김정용 Method for penile augmentation with autodermal cell culture
US6670184B2 (en) * 2000-06-23 2003-12-30 Basf Ag Method for producing a lipid emulsion for use in insect cell culture
US6635448B2 (en) * 2000-08-21 2003-10-21 Clonexdevelopment, Inc. Methods and compositions for increasing protein yield from a cell culture
US7211209B2 (en) * 2000-11-08 2007-05-01 Surface Logix, Inc. Method of making device for arraying biomolecules and for monitoring cell motility in real-time
US6495340B2 (en) * 2000-11-28 2002-12-17 Medis El Ltd. Cell carrier grids
US6588586B2 (en) * 2000-12-08 2003-07-08 Biocrystal Ltd Mailer for cell culture device
US6403369B1 (en) * 2001-01-19 2002-06-11 Gary W. Wood Cell culture vessel
US20020106715A1 (en) * 2001-02-02 2002-08-08 Medisel Ltd System and method for collecting data from individual cells
US6645757B1 (en) * 2001-02-08 2003-11-11 Sandia Corporation Apparatus and method for transforming living cells
US6544788B2 (en) * 2001-02-15 2003-04-08 Vijay Singh Disposable perfusion bioreactor for cell culture
WO2002092778A2 (en) * 2001-05-17 2002-11-21 The Board Of Trustees Of The Leland Stanford Junior University Device and method for three-dimensional spatial localization and functional interconnection of different types of cells
KR20020088848A (en) * 2001-05-21 2002-11-29 (주)코아바이오텍 Cell Culture Tube and Multiple Roller Tube Cell Culture System Using The Same
EP1395366B1 (en) * 2001-06-14 2006-05-03 Millipore Corporation Multiwell test apparatus
WO2003008943A1 (en) * 2001-07-19 2003-01-30 Tufts University Optical array device and methods of use thereof for screening, analysis and manipulation of particles
EP1438385A1 (en) * 2001-10-25 2004-07-21 Bar-Ilan University Interactive transparent individual cells biochip processor
US20030189850A1 (en) * 2002-04-09 2003-10-09 Toyo Boseki Kabushiki Kaisha Cell array system
JP2004344036A (en) * 2003-05-21 2004-12-09 Fujitsu Ltd Substance-transducing device and substance-transducing system
US20050064524A1 (en) * 2003-08-11 2005-03-24 Mordechai Deutsch Population of cells utilizable for substance detection and methods and devices using same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5905031A (en) * 1995-05-18 1999-05-18 Coulter International Corp. Identification of blast cells in a leukocyte cell preparation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1287160A2 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7405071B2 (en) 2003-02-27 2008-07-29 Seng Enterprises Ltd. Method and device for manipulating individual small objects
US7888110B2 (en) 2003-06-26 2011-02-15 Seng Enterprises Ltd. Pico liter well holding device and method of making the same
US10190082B2 (en) 2003-06-26 2019-01-29 Seng Enterprises Ltd. Multiwell plate
US7403647B2 (en) 2004-09-13 2008-07-22 Seng Enterprises Ltd. Method for identifying an image of a well in an image of a well-bearing component
US8409509B2 (en) 2007-04-12 2013-04-02 Regents Of The University Of Minnesota Systems and methods for analyzing a particulate
US9739699B2 (en) 2007-11-15 2017-08-22 Seng Enterprises Ltd. Device for the study of living cells
US9975118B2 (en) 2007-11-15 2018-05-22 Seng Enterprises Ltd. Device for the study of living cells

Also Published As

Publication number Publication date
EP1287160A4 (en) 2004-12-29
JP2003533209A (en) 2003-11-11
WO2001088176A3 (en) 2002-04-11
US20030211458A1 (en) 2003-11-13
AU6056501A (en) 2001-11-26
EP1287160A2 (en) 2003-03-05
IL136232A0 (en) 2001-05-20

Similar Documents

Publication Publication Date Title
US20030211458A1 (en) Measurements of enzymatic activity in a single, individual cell in population
Wolfbeis et al. Reversible optical sensor membrane for hydrogen peroxide using an immobilized fluorescent probe, and its application to a glucose biosensor
US6210910B1 (en) Optical fiber biosensor array comprising cell populations confined to microcavities
Chan et al. Rapid image-based cytometry for comparison of fluorescent viability staining methods
Caron et al. Assessment of bacterial viability status by flow cytometry and single cell sorting
US20090104652A1 (en) Method and apparatus for viable and nonviable prokaryotic and eukaryotic cell quantitation
US20070105089A1 (en) Interactive transparent individual cells biochip processor
Klos-Witkowska Enzyme-based fluorescent biosensors and their environmental, clinical and industrial applications.
Jones et al. [22] Assays of plasma membrane NADPH oxidase
US6555360B1 (en) Flow injection flow cytometry system for on-line monitoring of biroreactors and method for monitoring
NL8003987A (en) COMPOSITION FOR THE EXAMINATION OF ORGANIC TISSUES AND / OR LIQUIDS AND METHOD USE THEREOF.
Palková et al. Single‐cell analysis of yeast, mammalian cells, and fungal spores with a microfluidic pressure‐driven chip‐based system
EP0333560B1 (en) Process for quantitative determination of micro organismes
Khan et al. A fluorescence-based imaging-fiber electrode chemical sensor for hydrogen peroxide
Fereja et al. A high-efficiency cathodic sodium nitroprusside/luminol/H 2 O 2 electrochemiluminescence system in neutral media for the detection of sodium nitroprusside, glucose, and glucose oxidase
JPH1042895A (en) Detection of enzyme, composition therefor and test specimen therefor
Tamiya et al. Luminol-based electrochemiluminescent biosensors for highly sensitive medical diagnosis and rapid antioxidant detection
Sunray et al. Determination of individual cell Michaelis‐Menten constants
O'Donovan et al. Development of a respirometric biochip for embryo assessment
CA2427106C (en) Method and apparatus for prokaryotic and eukaryotic cell quantitation
AT390803B (en) METHOD FOR DETERMINING THE CONCENTRATION OF AN ENZYME SUBSTRATE AND SENSOR FOR IMPLEMENTING THE METHOD
CN101389766A (en) Lipovrotein sensor
Gao et al. Highly sensitive real-time detection of intracellular oxidative stress and application in mycotoxin toxicity evaluation based on living single-cell electrochemical sensors
CN112179877A (en) Method for detecting inorganic pyrophosphatase based on catalytic reaction in-situ fluorescence
Hutter et al. Detection of proteinases in Saccharomyces cerevisiae by flow cytometry

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2001934272

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001934272

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10276080

Country of ref document: US

WWR Wipo information: refused in national office

Ref document number: 2001934272

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001934272

Country of ref document: EP